SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is actively trending as market participants analyze former President Trump's speech at the World Economic Forum in Davos. His remarks, particularly those concerning Greenland and the broader economic outlook, are sparking intense debate within the community. Discussion centers on whether his bullish pronouncements or controversial international rhetoric will ultimately dictate market sentiment amid geopolitical tensions.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending as Donald Trump's remarks at the World Economic Forum captivate audiences, with community attention centered on his controversial proposals for tariffs and persistent calls to acquire Greenland. These statements are fueling polarized debates regarding their potential impact on international relations and market stability, alongside widespread commentary on his public speaking style.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending after its Q4 earnings report, which, despite solid subscriber growth and ad revenue, prompted a significant stock decline due to conservative Q1 guidance and investor concerns over the proposed Warner Bros. Discovery acquisition. The community is sharply divided; bulls view the deep pullback as an oversold opportunity given strong long-term fundamentals and content potential, while bears focus on the acquisition's cost, debt implications, and paused share buybacks as potential headwinds for future profitability.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is trending following news that its subsidiary, Lucid Diagnostics, was awarded a contract by the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test. This development has ignited widespread community discussion, with many highlighting the stock's low share float and speculating about a potential short squeeze, drawing parallels to other recent volatile small-cap movements. Community members are actively debating the contract's impact on PAVmed's valuation, especially given its significant ownership stake in Lucid.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to widespread market discussion around geopolitical tensions, specifically former President Trump's rhetoric on Greenland and trade policy during his Davos address. The community is actively debating whether perceived softening in his stance will alleviate pressure or if broader concerns over trade relations and central bank policy will continue to influence growth-oriented tech assets.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is experiencing heightened investor attention and bullish momentum as multiple analyst upgrades and anticipation of its upcoming earnings report fuel a narrative of a strong turnaround. The community is actively discussing its resilience and upward trajectory, particularly given its performance on down market days, with many highlighting its strategic position in AI and domestic manufacturing capabilities amidst robust demand.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network (BNAI) is a top trending stock after securing a $2.05 million AI licensing partnership in Africa, which includes a pilot program with Nelson Mandela University. The community is intensely focused on the stock's notably low float and high short interest, driving widespread discussion about a potential squeeze. While many anticipate further upside, others express caution, debating the valuation in light of the deal size and raising concerns about potential volatility.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is experiencing intense community discussion, fueled by recent high-grade silver drill results and a broadly bullish sentiment across precious metals markets. Investors are actively debating the company's valuation, weighing its significant resource potential and strategic investor interest against its current pre-production status and capital requirements.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is a major discussion point after announcing it met revised 2025 production targets and increased vehicle deliveries, boosted by the Gravity SUV, alongside news of a robotaxi alliance with Uber and Nuro. While some investors see this as a sign of operational progress, community sentiment remains divided, with concerns over long-term profitability, cash burn, and leadership driving ongoing, intense debate within the challenging EV market.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is actively discussed following positive FDA guidance that sets a path for expanded use of its ANKTIVA treatment for bladder cancer, with the community noting no new trials are required and a resubmission timeline established. Investors are highly engaged, anticipating further global approvals
including for lung cancer
and future catalysts like AI-driven manufacturing, fueling strong conviction amidst persistent short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merck & Co., Inc. $MRK Stock Position Boosted by Joel Isaacson & Co. LLC

Joel Isaacson & Co. LLC raised its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 34.3% in the third quarter, according to the company in its most recent 13F filing with the SEC...

Dynasty Wealth Management LLC Takes $1.02 Million Position in Merck & Co., Inc. $MRK

Dynasty Wealth Management LLC bought a new position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange...

<ul class="summary-bullets"><li>BofA lifted its price target to $27 from $24 while keeping an 'Underperform' rating on the shares.</li><li>The update followed the release of five-year follow-up results for the Intismeran vaccine used alongside Keytruda in melanoma patients.</li><li>Moderna and Merck said additional data from the study will be shared at an upcoming medical meeting.</li></ul>Moderna Inc. shares were in focus on Wednesday after Bank of America Securities (BofA) raised its price target on the stock following new long-term data from the company’s experimental skin cancer vaccine developed with Merck, while keeping a bearish rating in place.Merck shares rose 0.6% in regular trading before slipping 0.6% after hours, while Moderna climbed 2.8% during the session and edged 0.2% lower in extended trading.<h2 class="st-heading-2">Price Target Raised, Rating Maintained</h2>BofA raised its price target on Moderna to $27 from $24 and reiterated an ‘Underperform’ rating on the shares. However, based on Moderna’s last closing price of $43, the updated target&nbsp;still implies about a 37% downside.The firm said the increase followed the release of five-year data for Intismeran Autogene, Moderna’s personalized cancer vaccine, used in combination with Merck’s Keytruda in patients with high-risk melanoma.While noting some upside potential, the brokerage pointed to challenges seen in similar combination treatments in the past, logistical challenges, and a “higher bar for success.” BofA said the higher price target reflects increased sales expectations for the vaccine in patients who have undergone surgery for melanoma.<h2 class="st-heading-2">Five-Year Skin Cancer Results</h2>Moderna and Merck said the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">latest follow-up</a> showed the vaccine combination continued to help patients remain cancer-free for longer than Keytruda alone.After five years, patients who received the combination saw a 49% lower risk of the cancer returning or leading to death than those treated with Keytruda by itself. The companies said the findings build on earlier updates shared at the two-year and three-year marks. Moderna and Merck also said they plan to share additional follow-up results at an upcoming medical meeting.<h2 class="st-heading-2">Oncology Pipeline Progress</h2>“Now with five years of follow-up data, today's results highlight the potential of a prolonged benefit of the intismeran autogene and Keytruda combination in patients with resected high-risk melanoma,” said Kyle Holen, Moderna’s head of oncology development.Holen said the company continues to invest in cancer research and is preparing for several upcoming milestones, including results from a late-stage melanoma study being run with Merck, as well as progress across eight ongoing studies in different cancer types. Meanwhile, Merck’s head of oncology, Marjorie Green, said the long-term results are encouraging for patients&nbsp;at high risk of the disease returning after surgery.Moderna said it is continuing to expand its cancer treatment work alongside its vaccine business. The company and Merck are currently running or enrolling studies across several cancers, including lung, bladder, kidney, and melanoma, as part of their joint development program for the vaccine.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘neutral’ for Moderna and ‘bearish’ for Merck, with both seeing ‘normal’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_65694a07b3.webp" alt="mrna ss.png" width="969" height="140"><figcaption>MRNA sentiment and message volume as of January 20 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/mrk_ss_png_42eb55ab2c.webp" alt="mrk ss.png" width="961" height="141"><figcaption>MRK sentiment and message volume as of January 20 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/MRNA">Moderna’s stock</a> has risen 26% over the past 12 months, while Merck’s stock has jumped 16% over the same period.&nbsp;On Wall Street, analysts are largely neutral on MRNA, according to Koyfin data: 17 out of 24 analysts covering the stock recommend a ‘hold’ rating, while four have a ‘buy’ or ‘strong buy’ conviction, and the rest have a ‘sell’ rating. Their consensus price target of $​​36.75 leaves MRNA trading at a more than 14% premium.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious

BofA Securities said the target hike reflects higher sales expectations, despite logistics challenges.

Equity

Merck & Co., Inc. (NYSE:MRK) Stock Price Expected to Rise, TD Cowen Analyst Says

TD Cowen raised their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a "hold" rating in a research report on Tuesday...

<ul class="summary-bullets"><li>The clinically meaningful improvement in recurrence-free survival builds on the analyses conducted at about two years of follow-up as well as three years of follow-up.</li><li>Moderna and Merck said that they now plan to present further data from the follow-up at an upcoming medical meeting.</li><li>Moderna is currently seeking to pivot into oncology and rare-disease therapeutics.</li></ul>Moderna (MRNA) and Merck (MRK) said on Tuesday that their intismeran autogene vaccine based on messenger RNA (mRNA), in combination with cancer drug Keytruda, reduced the risk of recurrence or death by 49% in certain patients with high-risk melanoma on five years of follow-up when compared to Keytruda alone.The improvement was <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=7585547225835569&amp;symbol=MRNA">observed</a> in patients with stage III/IV melanoma who had complete removal of their tumors. Melanoma is a serious form of skin cancer characterized by the uncontrolled growth of pigment-producing cells.Moderna and Merck said that they now plan to present further data from the follow-up at an upcoming medical meeting.<h2 class="st-heading-2">Executives’ Take</h2>The clinically meaningful improvement in recurrence-free survival builds on the analyses conducted at about two years of follow-up, as well as three years of follow-up, the companies said."We continue to invest in our platform in oncology because of encouraging outcomes like these, which illustrate mRNA's potential in cancer care. We look forward to several additional milestones to come, including the results of our Phase 3 study in adjuvant melanoma in collaboration with Merck, and continued progress across the eight Phase 2 and Phase 3 studies in multiple tumor types and patient populations," Moderna's Senior Vice President and Head of Development of Oncology and Therapeutics Kyle Holen said.Moderna is currently seeking to pivot into oncology and rare-disease therapeutics. "Over the next three years, we expect to build a large seasonal vaccine franchise for at-risk populations and invest the cash generated into oncology and rare disease therapeutics," CEO Stéphane Bancel <a href="https://stocktwits.com/news-articles/markets/equity/moderna-procures-1.5-billion-loan-to-grow-its-pipeline-beyond-vaccines/cLPA0dfREaR">said</a> in November.Investment in late-stage oncology and rare disease programs will set the company up for additional growth in 2027 and 2028, as per the firm.Shares of MRNA traded 1.1% higher at the time of writing while MRK stock traded marginally in the red.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRNA stock fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume dipped from ‘extremely high’ to ‘high’ levels.Meanwhile, sentiment around MRK shares stayed within the ‘neutral’ territory, coupled with ‘normal’ message volume.A Stocktwits user opined that the news is “solid” for Moderna’s oncology segment.<stembedurl>https://www.stocktwits.com/MobyOneCanobi/message/642290058</stembedurl>Another user voiced hopes for the stock crossing the $50/share price this week.<stembedurl>https://www.stocktwits.com/Raven67/message/642288562</stembedurl><a href="https://stocktwits.com/symbol/MRNA">MRNA shares</a> have gained 18% over the past 12 months while <a href="https://stocktwits.com/symbol/MRK">MRK shares</a> have gained 13%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mu-stock-analyst-target-hikes-how-much-upside-does-retail-expect/cmUuYEzR4Ob">MU Stock Garners Attention Amid Analyst Target Hikes — How Much Upside Does Retail Expect?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update

Intismeran autogene vaccine, in combination with cancer drug Keytruda, reduced the risk of recurrence or death at five years of follow-up, the company said. 

Will Weak Gardasil Sales Continue to Ail MRK Revenues in Q4 Earnings?

Gardasil's sharp sales slump in China and Japan puts Merck under pressure heading into Q4 earnings, with the vaccine's sales expected to stay under strain.

Turtle Creek Wealth Advisors LLC Cuts Position in Merck & Co., Inc. $MRK

Turtle Creek Wealth Advisors LLC lowered its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 68.1% during the 3rd quarter, according to its most recent filing with the Securities & Exchange...

CytomX Stock Rises 31% in a Month: Here's What You Should Know

CTMX's share jumps 31% in a month after it outlined pipeline progress and 2026 goals led by Varseta-M in advanced colorectal cancer.

NorthCrest Asset Manangement LLC Buys 81,276 Shares of Merck & Co., Inc. $MRK

NorthCrest Asset Manangement LLC lifted its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 52.9% during the 3rd quarter, according to the company in its most recent 13F filing...

Wealth Enhancement Advisory Services LLC Acquires 98,009 Shares of Merck & Co., Inc. $MRK

Wealth Enhancement Advisory Services LLC increased its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 5.9% in the third quarter, according to its most recent Form 13F filing with the...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MRK News

MRKMerck & Co Inc